Compare Immunovant Inc. Common Stock (IMVT) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Tilray Brands Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Tilray Brands Inc trades at $3.64 (market cap $549.01M). The key difference: Immunovant Inc. Common Stock is far larger — about 12.1× Tilray Brands Inc's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Tilray Brands Inc for 31 Days on average.
| IMVT | TLRY | |
|---|---|---|
Market Cap | $6.62B | $549.01M |
Volume | 1,131,364 | 3,292,073 |
Sector | Health | Health |
52-Week High | $44.96 | $21.00 |
52-Week Low | $17.03 | $3.57 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $5.72B | $716.15M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tilray Brands (TLRY) trades at $3.715, down 1.72% on the day, as the stock continues to face significant pressure with bearish technical signals and fundamental challenges. The company reported a substantial net loss of $2.19 billion in 2025 despite $821 million in revenue, with negative cash flow from operations of $94.6 million. Recent earnings have consistently missed expectations, and technical indicators show a bearish trend with the stock trading near key support levels.
While TLRY shows attractive valuation metrics with P/S of 0.45 and P/B of 0.34, the company faces substantial execution risks amid persistent losses and negative cash flow. Analyst sentiment remains cautious with only 25% buy ratings, though the consensus price target of $65.01 suggests significant upside potential if the company can achieve profitability and growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
